Volume 90 Issue 12 | pp. 22-25
Issue Date: March 19, 2012

Tough Times For Neuroscience R&D

With failed trials and few new drugs, big pharma is overhauling neuroscience research
Department: Business | Collection: Economy
Keywords: neuroscience, CNS, pharmaceuticals, drug discovery, Alzheimer’s

When AstraZeneca revealed plans last month to step away from internal neuroscience R&D, the European College of Neuropsychopharmacology released a statement expressing alarm that yet another big pharma firm was pulling out of the field. “There is a growing sense that neuroscience in Europe is now facing a severe crisis,” the group said.

AstraZeneca had joined its competitors Novartis and GlaxoSmithKline in significantly cutting the number of scientists working . . .

To view the rest of this content, please log in with your ACS ID.



 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society